NOMIN PARK: Open Payments
NPI 1801645742 · MEDFORD, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,205 in 87 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $61 · 2025 $2,205
Food & beverage: $2,205
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 8 | $341 |
| Novo Nordisk Inc | 9 | $287 |
| Otsuka America Pharmaceutical, Inc. | 4 | $190 |
| Ardelyx, Inc. | 8 | $174 |
| Lilly USA, LLC | 3 | $170 |
| AstraZeneca Pharmaceuticals LP | 9 | $168 |
| ABBVIE INC. | 11 | $142 |
| Sumitomo Pharma America, Inc. | 5 | $109 |
| PFIZER INC. | 3 | $71 |
| Astellas Pharma US Inc | 3 | $68 |
Products named: Ozempic, REXULTI, IBSRELA, REPATHA, EVENITY, GEMTESA, AIRSUPRA, Veozah.
Industry payments across OR — which companies pay providers there.
